Periodic Reporting for period 1 - PNMS (Extending the applicability of Cryo-EM for fragile biological systems via ultra-pure cryo-samples from Preparative Native Mass Spectrometry)
Reporting period: 2020-06-01 to 2022-05-31
Cryo electron microscopy (cryo-EM) has become the method of choice to obtain high (often atomic) resolution structures of protein complexes that are not amenable to alternative techniques like X-ray crystallography or nuclear magnetic resonance. Despite major advances, sample preparation is typically the main bottleneck of the cryo-EM workflow. Challenges include denaturation of proteins at the air-water interface, sample heterogeneity, and inhomogeneous ice-thickness. All of these effects can decrease resolution and thus hide structural information.
Complementary information, in particular from mass spectrometry (MS) based techniques can help to find optimal sample conditions, interpret and refine 3D structures, reveal native binding sites and strength, and provide information on small ligands and flexible protein regions. By combining native MS and electrospray ion-beam deposition (ES-IBD) into a novel workflow, termed native ES-IBD, the current project aimed at making preparation of cryo-EM samples of protein complexes more reliable and selective and allow for unambiguous assignment of complementary information from mass spectrometry to high-resolution structures from cryo-EM.
Using native ES-IBD and cryo-EM, mass-selected and ice-free samples were prepared and imaged, demonstrating high contrast as well as control over particle distribution, deformation, and dissociation. Corresponding 2D classes and 3D EM density maps show that the overall shape of protein assemblies is largely preserved. Small structural changes due to dehydration, landing, or surface interaction limit resolution. Instrumentation was developed to control temperature and hydration which may allow to overcome these limitations in the future. The results imply that the native ES-IBD may lead to an acceleration of drug development if the current limitations can be overcome.
A cryogenically cooled landing stage was implemented to control temperature and hydration throughout the workflow. It forms the basis for variations of the workflow that include controlled rehydration, which is essential to retain or regain native solution phase structures. Unfortunately, COVID-19 related delays in the delivery of essential parts delayed completion until shortly after the end of the project.
The results were presented at the conference for Isolated Biomolecules and Biomolecular Interactions (IBBI) in 2022. Further disseminations shortly after the end of the project include talks at the International Mass Spectrometry Conference (IMSC) 2022, the Faraday discussion on “Challenges in biological cryo electron microscopy” in 2022, and the workshop “Frontiers in Native Mass Spectrometry and Single-Molecule Imaging”, co-organized by the researcher. A preprint focusing on general instrument performance and applications as posted to arxiv and submitted to a high-impact journal. It is, as of July 2022, in minor revision. A publication on the specific use for cryo-EM sample preparation has been accepted by PNAS Nexus. A third paper focusing on the choice of the substrate and surface induced dissociation has been accepted as part of the Faraday discussion mentioned above. Thermo Fisher Scientific and the University of Oxford have filed a joint patent application concerning variations of the workflow beyond the action. The close collaboration with Thermo Fisher Scientific on this project resulted in a unique opportunity for the fellow to join the company while being able to complete construction and characterization of the cryo landing stage at the University of Oxford.
The unique instrumentation developed as part of this project has the potential to greatly improve cryo-EM sample preparation. The high level of reproducibility and control implies a large potential to reduce time and cost while maintaining near native structure. The project showed that these objectives are closer to being realized than previously anticipated by the adjacent communities.
As the approach is based on a widely available commercial instrument, it can be adopted by other labs with reasonable effort. Thus, applications can be scaled up quickly and have the potential to significantly accelerate drug development.